Reston Equity Group is a location-agnostic, operationally focused independent sponsor with a current presence in Kentucky, Ohio, and Virginia. In Q4 2022, we successfully acquired a portfolio of seven home services companies, swiftly implementing turnaround strategies that have leveraged our internal expertise in operational optimization and strategic management, setting them on a trajectory toward enhanced profitability. As we continue to grow, we are actively pursuing expansion opportunities in business services, health & wellness, and scientific instrumentation, drawing upon the knowledge and skills of our leadership team. We plan to utilize our extensive network of capital partners to fuel our growth initiatives and enhance our existing portfolio both horizontally and vertically.

- Consulted clients in Southeastern US at every organizational level to facilitate product development and cost reduction, resulting in 40% year-over-year (2021-2022) growth and 143% growth vs. previous 4-year average (2018-2021)- Guided and coached new hires, including Application Engineer, Customer Experience Specialist, and Technical Business Strategist, producing a seamless role transition and leading to 12% year-over-year (2020-2021) growth for Southwestern US- Oversaw every aspect of account management across multiple product lines in 3 different territories (16 states and the Caribbean), yielding $3.3M in revenue (2018-2022, 106% of cumulative set target) and 3 Sales Excellence Awards- Attended International Growth Strategy meeting, participated in 3 advanced training sessions at Worldwide HQ in Austria, and invited to serve on Global Product Line Marketing Board with international colleagues

- Responsible for account management and business objectives of entire Milestone product portfolio and conducted 85 face-to-face meetings across 8 states in 6 months, securing 96% of revenue target in first complete quarter (Q2 2018)

- Supervised, mentored and trained other lab members (research associates, grad students, postdocs) in a highly radioactive environment with emphasis on radiation safety and the use of automated radiosynthesizers - Developed [18F]-radiotracers for clinical delivery and preclinical research in a fast-paced setting (18F half-life = 109 min), providing patients with time-sensitive, lifesaving measures

- Prepared and delivered lectures and exams to students with diverse backgrounds in class sizes ranging from 50-125, influencing over 500 undergraduates in 12 different classes, leading to hundreds of positive reviews on ratemyprofessors.com- Drafted over 50 letters of recommendation for students pursuing graduate studies, many of whom have enrolled in medical school, dental school, or Ph.D. programs

- Spearheaded joint venture with UCLA by developing analytical methods and performing quality control testing, enabling operational qualification and validation of primary product (automated radiosynthesizer platform)- Completed Radiation Safety Officer (RSO) training course and appointed as Radiation Safety Officer of the laboratory, ensuring a safe and productive atmosphere for team members and collaborators in a startup setting

- Planned and conducted experiments to facilitate product launch- Worked on development of test methods for nuclear pharmaceuticals- Sourced and tested robotic devices

- Led, supervised and completed commercial transfer reaction scale-up of preliminary drug synthesis from academia to industrial startup location, resulting in successful product launch and personnel expansion from 30 in 2014 to 200+ at present day- API synthesis development project team- Performed raw materials identification, sourcing and characterization- Developed raw material specifications- Supervised preliminary drug synthesis for commercial transfer

- Collaborated with NASA and successfully conducted small-scale proof-of-concept drug design experiments for consulting project while concluding graduate research and finishing Ph.D. dissertation- Designed apparatus for initial drug production- Synthesized and characterized drug under non-GMP conditions and quantitatively identified impurities- Conducted research to develop new drug manufacturing process

- Managed and conducted research on Department of Defense/Defense Threat Reduction Agency (DoD/DTRA) funded project (~$1M) focused on decontamination of biological/chemical weapons of mass destruction (e.g. nerve agents) using laser assisted catalysis and functionalized gold nanoparticles- Awarded National Science Foundation (NSF) Fellowship in 2011 with East Asia and Pacific Summer Institutes for U.S. Graduate Students (EAPSI) for study at University of Otago in Dunedin, New Zealand- Collaborated with 13 researchers and the Naval Research Laboratory to publish 3 peer-reviewed scientific articles in Journal of Nanoparticle Research (2014), Dalton Transactions (2013) and Acta Crystallographica (2011)- Presented posters at Chemical and Biology Defense Science and Technology Conference (2011, Las Vegas, NV), 244th ACS National Meeting (2012, Philadelphia, PA) and 40th International Conference on Coordination Chemistry (2012, Valencia, Spain)- Studied the synthesis, reactivity and characterization of pentamminecobalt(III) complexes- Supervised and trained graduate and undergraduate students- Taught general chemistry lab courses to undergraduate students

- East Asia and Pacific Summer Institute (EAPSI) fellow- Funded by National Science Foundation (NSF) and the Royal Society of New Zealand- Advisor: Prof. Allan Blackman- Investigated the characterization of cobalt(III) coordination compounds using 59Co NMR spectroscopy and XRD